Labeling compliance burden comments sought
This article was originally published in The Tan Sheet
Executive Summary
Roughly 500 nonprescription drugs introduced annually through new drug applications or abbreviated NDAs must comply with FDA's standardized format and content requirements for labeling marketed OTC drug products. In a June 3 Federal Register notice seeking comments on a proposed collection of information on industry's burden for compliance with the 1999 OTC labeling final rule, FDA says the Consumer Healthcare Products Association provided data for the estimate. The notice also says some 4,750 OTC sunscreen stock-keeping units have not complied with the labeling rule, but need to by a date the agency will set when it publishes a final rule for the OTC sunscreen monograph. FDA estimates firms need five hours to prepare labeling for OTC NDAs and ANDAs and two hours for sunscreen labeling prior to submitting the information to the agency. Monograph OTC drugs already must comply with the labeling rule. The deadline for comments is Aug. 3
You may also be interested in...
EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: